Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an update.
Clarity Pharmaceuticals has issued 25,000 fully paid ordinary shares following the exercise of options, without the need for disclosure under the Corporations Act. This move indicates Clarity’s compliance with relevant legal provisions and reflects its ongoing operational activities, potentially impacting its market position and stakeholder interests.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company specializing in the development of innovative radiopharmaceuticals. The company focuses on targeted copper theranostics for treating cancer in both children and adults, leveraging its SAR Technology Platform.
YTD Price Performance: -14.63%
Average Trading Volume: 1,689,817
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$1.14B
For an in-depth examination of CU6 stock, go to TipRanks’ Stock Analysis page.